Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Peritoneal Metastases From Gastric Cancer 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 8Radiotherapy 7Fluorouracil 6Neoadjuvant Therapy 4Irinotecan 4pembrolizumab 3Paclitaxel 3Gefitinib 3Carboplatin 3toripalimab 2spartalizumab 2Oxaliplatin 2Nivolumab 2Esophagectomy 2Docetaxel 2vandetanib 1tislelizumab 1sitravatinib 1ribociclib 1oblimersen 1nazartinib 1liposomal doxorubicin 1apatinib 1Surgical Procedures, Operative 1SGN-LIV1A 1Proton Therapy 1Pemetrexed 1Panitumumab 1Nutritional Support 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Esophageal Squamous Cell Carcinoma × apatinib × Clear all
NCT03251417 2023-02-01

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Terminated
11 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡